Report cover image

Global Biosimilars Market Size & Share to 2027

Publisher QualiKet Research
Published Apr 29, 2022
Length 179 Pages
SKU # QUA17148405

Description

Global Biosimilars Market Size & Share to 2027

Global Biosimilars Market Size, Trends & Growth Opportunity, By Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Fusion Proteins, Insulin, Monoclonal Antibodies, Erythropoietin, Follitropin, Anticoagulants, and others, by therapy type such as Immunology, Oncology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), By Therapy Type, By Distribution Channel, By Region and Forecast till 2027

Global Biosimilars Market

Biosimilars are highly identical to approved biological drugs. They have similar properties in terms of safety, potency, and efficacy to original biologic products but they have minor differences in clinically inactive components. Regulations for biosimilars play important role in maintaining the viability and balance between reference product and biosimilars product. Various regulatory authorizes like FDA and EMA actively regulate the development and commercialization of biosimilars.

Market Drivers

The rise in number of biosimilar approvals is the key driving factor which is expected to boost the global biosimilars market growth. For instance, in July 2018, the USFDA (U.S. Food and Drug Administration) had introduced a biosimilars action plan to encourage the development of biosimilars. Furthermore, increases in prevalence of chronic diseases like cancer will positively contribute the market growth. For instance, in 2018, as per the NCI (National Cancer Institute) information approximates 1,735,350 new cases of cancer likely to be diagnosed in United States. Moreover, increase in research and development activities as well as government initiatives will fuel the global biosimilars market growth during this forecast period. Many governments are emphasizing on cost-effective drug synthesis. The united Ststes is the popular country with highest health expenditure.

Market Restraints

However, a complexity in manufacturing is the major restraining factor which is expected to hinder the global biosimilars market growth. Also, stringent rules and regulations for development and manufacturing of biosimilars will affect the market growth.

Market Segmentation

Global Biosimilars Market is segmented into drug class such as Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Fusion Proteins, Insulin, Monoclonal Antibodies, Erythropoietin, Follitropin, Anticoagulants, and others, by therapy type such as Immunology, Oncology, Hematology, Hormone Therapy, Metabolic Disorders, and Others. Further, market is segmented into distribution channel such as Hospital Pharmacies, Retail Pharmacies, and Speciality Pharmacies.

Also, Global Biosimilars Market is segmented into is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Market Key Players

Various key players are discussed in this report such as Novartis AG, Pfizer Inc. Celltrion Healthcare Co., Ltd, Teva Pharmaceutical, Biocon Limited, Dr. Reddy's Laboratories, Amgen, Inc.,and Sanofi S.A.

Market Taxonomy

By Drug Class
  • Recombinant Human Growth Hormone
  • Granulocyte Colony-Stimulating Factor
  • Fusion Proteins
  • Insulin
  • Erythropoietin
  • Monoclonal Antibodies
  • Follitropin
  • Anticoagulants
  • Others
By Therapy Type
  • Immunology
  • Oncology
  • Hematology
  • Hormone Therapy
  • Metabolic Disorders
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Key Questions Addressed by the Report
  • What are the Key Opportunities in Global Biosimilars Market?
  • What will be the growth rate from 2019 to 2027?
  • Which segment/region will have highest growth?
  • What are the factors that will impact/drive the Market?
  • What is the competitive Landscape in the Industry?
  • What is the role of key players in the value chain?
  • What are the strategies adopted by key players?

Table of Contents

179 Pages
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Biosimilars Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Biosimilars Market, By Drug Class
5.1 Y-o-Y Growth Comparison, By Drug Class
5.2 Global Biosimilars Market Share Analysis, By Drug Class
5.3 Global Biosimilars Market Size and Forecast, By Drug Class
5.3.1 Recombinant Human Growth Hormone
5.3.2 Granulocyte Colony-Stimulating Factor
5.3.3 Fusion Proteins
5.3.4 Insulin
5.3.5 Monoclonal Antibodies
5.3.6 Erythropoietin
5.3.7 Follitropin
5.3.8 Anticoagulants
5.3.9 Others
6 Global Biosimilars Market, By Therapy Class
6.1 Y-o-Y Growth Comparison, By Therapy Class
6.2 Global Biosimilars Market Share Analysis, By Therapy Class
6.3 Global Biosimilars Market Size and Forecast, By Therapy Class
6.3.1 Immunology
6.3.2 Oncology
6.3.3 Hematology
6.3.4 Hormone Therapy
6.3.5 Metaboloc Disorders
6.3.6 Others
7 Global Biosimilars Market, By Distribution Channel
7.1 Y-o-Y Growth Comparison, By Distribution Channel
7.2 Global Biosimilars Market Share Analysis, By Distribution Channel
7.3 Global Biosimilars Market Size and Forecast, By Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Specialty Pharmacies
8 Global Biosimilars Market, By Region
8.1 Global Biosimilars Market Share Analysis, By Region
8.2 Global Biosimilars Market Share Analysis, By Region
8.3 Global Biosimilars Market Size and Forecast, By Region
9 North America Biosimilars Market Analysis and Forecast (2020-2027)
9.1 Introduction
9.2 North America Biosimilars Market Share Analysis, By Drug Class
9.3 North America Biosimilars Market Size and Forecast, By Therapy Class
9.4 North America Biosimilars Market Size and Forecast, By Distribution Channel
9.5 North America Biosimilars Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10 EuropeBiosimilars Market Analysis and Forecast (2020-2027)
10.1 Introduction
10.2 Europe Biosimilars Market Share Analysis, By Drug Class
10.3 Europe Biosimilars Market Size and Forecast, By Therapy Class
10.4 Europe Biosimilars Market Size and Forecast, By Distribution Channel
10.5 Europe Biosimilars Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.5.4 Rest of Europe
11 Asia Pacific Biosimilars Market Analysis and Forecast (2020-2027)
11.1 Introduction
11.2 Asia Pacific Biosimilars Market Share Analysis, By Drug Class
11.3 Asia Pacific Biosimilars Market Size and Forecast, By Therapy Class
11.4 Asia Pacific Biosimilars Market Size and Forecast, By Distribution Channel
11.5 Asia Pacific Biosimilars Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Rest of Asia Pacific
12 Latin America Biosimilars Market Analysis and Forecast (2020-2027)
12.1 Introduction
12.2 Latin America Biosimilars Market Share Analysis, By Drug Class
12.3 Latin America Biosimilars Market Size and Forecast, By Therapy Class
12.4 Latin America Biosimilars Market Size and Forecast, By Distribution Channel
12.5 Latin America Biosimilars Market Size and Forecast, Country
13 Middle East Biosimilars Market Analysis and Forecast (2020-2027)
13.1 Introduction
13.2 Middle East Biosimilars Market Share Analysis, By Drug Class
13.3 Middle East Biosimilars Market Size and Forecast, By Therapy Class
13.4 Middle East Biosimilars Market Size and Forecast, By Distribution Channel
13.5 Middle East Biosimilars Market Size and Forecast, By Country
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Novartis AG
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. Pfizer Inc
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Celltrion Healthcare Co., Ltd
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Teva Pharmaceutical
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Biocon Limited
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Dr. Reddy's Laboratories
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Amgen, Inc
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Sanofi S.A.
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us